多奈单抗在早期阿尔茨海默病治疗中的研究

Research of Donanemab in the Treatment of Early Alzheimer's Disease

多奈单抗为一种β淀粉样蛋白(Aβ)靶向单克隆抗体,于2024年7月获美国食品药品监督管理局批准上市。相比于其他Aβ靶向药物,多奈单抗可特异性结合Aβp3-42氨基末端焦谷氨酸靶点,从而有效清除大脑中淀粉样蛋白斑块。研究表明,多奈单抗可显著减缓早期阿尔茨海默病患者的认知功能下降、延缓疾病进展,其常见不良反应为淀粉样蛋白相关的影像学异常、输液相关反应和药物过敏反应等。

Donanemab,an amyloidβ-protein(Aβ)targeted monoclonal antibody,was approved for marketing by the Food and Drug Administration in July 2024.In contrast to other Aβ-targeted agents,donanemab specifically binds to the target Aβp3-42 amino-terminal pyroglutamate,thereby effectively clearing amyloid plaques from the brain.Studies have shown that donanemab can significantly slow down cognitive decline and disease progression in patients with early Alzheimer's disease.There are common adverse reactions including amyloid-related imaging abnormalities,infusion-related reactions,and drug allergies.